ERBB2/ERBB3‑mutated S100/SOX10‑positive high‑grade uterine sarcoma-a case report on a rare entity.

IF 3.1 3区 医学 Q1 PATHOLOGY
Xingming Huang, Ying He, Wei Wang
{"title":"ERBB2/ERBB3‑mutated S100/SOX10‑positive high‑grade uterine sarcoma-a case report on a rare entity.","authors":"Xingming Huang, Ying He, Wei Wang","doi":"10.1007/s00428-025-04257-5","DOIUrl":null,"url":null,"abstract":"<p><p>ERBB2/ERBB3‑mutated S100/SOX10‑positive uterine sarcoma is a recently described entity with distinct morphological, immunophenotypic, and molecular features, representing a subset of high-grade uterine sarcomas. This tumor is characterized by ERBB2/ERBB3 mutations or ERBB2 amplification, which leads to the overexpression or constitutive activation of HER2. The presence of HER2 amplification represents a potential target for the treatment with HER2 inhibitors. Here we present a case of high-grade uterine cervix sarcoma with ERBB2 amplification and S100/SOX10 expression in a 58-year-old patient. The tumor measured 50 mm at its largest dimension and recurred two years after surgery. Histologically, the tumor was composed of round and spindle cell, showing diffuse nuclear expression of SOX10 and both nuclear and cytoplasm expression of S100. It also demonstrated ERBB2 amplification, as well as mutations in ATRX and BACH1. Accurate recognition of such tumors is crucial due to their propensity for aggressive behavior and the availability of potential targeted therapeutic options.</p>","PeriodicalId":23514,"journal":{"name":"Virchows Archiv","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Virchows Archiv","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00428-025-04257-5","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

ERBB2/ERBB3‑mutated S100/SOX10‑positive uterine sarcoma is a recently described entity with distinct morphological, immunophenotypic, and molecular features, representing a subset of high-grade uterine sarcomas. This tumor is characterized by ERBB2/ERBB3 mutations or ERBB2 amplification, which leads to the overexpression or constitutive activation of HER2. The presence of HER2 amplification represents a potential target for the treatment with HER2 inhibitors. Here we present a case of high-grade uterine cervix sarcoma with ERBB2 amplification and S100/SOX10 expression in a 58-year-old patient. The tumor measured 50 mm at its largest dimension and recurred two years after surgery. Histologically, the tumor was composed of round and spindle cell, showing diffuse nuclear expression of SOX10 and both nuclear and cytoplasm expression of S100. It also demonstrated ERBB2 amplification, as well as mutations in ATRX and BACH1. Accurate recognition of such tumors is crucial due to their propensity for aggressive behavior and the availability of potential targeted therapeutic options.

ERBB2/ERBB3突变S100/SOX10阳性高级别子宫肉瘤一例罕见病例报告
ERBB2/ERBB3突变的S100/SOX10阳性子宫肉瘤是最近发现的一种具有独特形态、免疫表型和分子特征的实体,代表了高级别子宫肉瘤的一个子集。这种肿瘤的特征是ERBB2/ERBB3突变或ERBB2扩增,导致HER2过表达或组成性激活。HER2扩增的存在代表了HER2抑制剂治疗的潜在靶点。我们报告一例58岁的高级别宫颈肉瘤,伴有ERBB2扩增和S100/SOX10表达。肿瘤最大尺寸为50毫米,术后两年复发。组织学上,肿瘤由圆形和梭形细胞组成,SOX10在细胞核中弥漫性表达,S100在细胞核和细胞质中均有表达。它还显示ERBB2扩增,以及ATRX和BACH1突变。由于这些肿瘤具有侵袭性行为的倾向和潜在的靶向治疗选择的可用性,因此准确识别此类肿瘤至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Virchows Archiv
Virchows Archiv 医学-病理学
CiteScore
7.40
自引率
2.90%
发文量
204
审稿时长
4-8 weeks
期刊介绍: Manuscripts of original studies reinforcing the evidence base of modern diagnostic pathology, using immunocytochemical, molecular and ultrastructural techniques, will be welcomed. In addition, papers on critical evaluation of diagnostic criteria but also broadsheets and guidelines with a solid evidence base will be considered. Consideration will also be given to reports of work in other fields relevant to the understanding of human pathology as well as manuscripts on the application of new methods and techniques in pathology. Submission of purely experimental articles is discouraged but manuscripts on experimental work applicable to diagnostic pathology are welcomed. Biomarker studies are welcomed but need to abide by strict rules (e.g. REMARK) of adequate sample size and relevant marker choice. Single marker studies on limited patient series without validated application will as a rule not be considered. Case reports will only be considered when they provide substantial new information with an impact on understanding disease or diagnostic practice.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信